Mark T. Iwicki Sells 5,779 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki sold 5,779 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $44,093.77. Following the transaction, the chief executive officer now directly owns 280,076 shares in the company, valued at $2,136,979.88. This represents a 2.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

KALA BIO Stock Up 2.1 %

KALA BIO stock traded up $0.16 during midday trading on Tuesday, hitting $7.69. 45,377 shares of the company were exchanged, compared to its average volume of 105,019. The company’s fifty day moving average price is $6.71 and its 200-day moving average price is $6.32. KALA BIO, Inc. has a fifty-two week low of $4.21 and a fifty-two week high of $9.25. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. The company has a market cap of $35.45 million, a PE ratio of -0.62 and a beta of -2.11.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, topping the consensus estimate of ($2.43) by $0.50. On average, research analysts predict that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP bought a new position in KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th largest holding. SR One Capital Management LP owned about 15.76% of KALA BIO as of its most recent SEC filing. 24.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of KALA BIO in a report on Friday, November 15th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.